Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study, Eur J Cancer, vol.51, issue.15, pp.2130-2143, 2015. ,
Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer, vol.110, pp.1429-1464, 2007. ,
HPV-associated head and neck cancer: a virus-related cancer epidemic, Lancet Oncol, vol.11, issue.8, pp.781-790, 2010. ,
Prevalence of human papillomavirus in oropharyngeal and non-oropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region, Head Neck, vol.35, issue.5, pp.747-55, 2013. ,
State-of-the-art management of locally advanced head and neck cancer, Br J Cancer, vol.92, issue.8, pp.1341-1349, 2005. ,
Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy? Head Neck, vol.20, pp.588-94, 1998. ,
Head and neck cancer: changing epidemiology, diagnosis, and treatment, Mayo Clin Proc, vol.83, issue.4, pp.489-501, 2008. ,
Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, issue.5, pp.184-190, 2010. ,
, A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group, Br J Cancer, 1990.
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck, J Clin Oncol, vol.10, issue.2, pp.257-63, 1992. ,
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study, J Clin Oncol, vol.10, issue.8, pp.1245-51, 1992. ,
, Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group, J Clin Oncol, vol.23, issue.15, pp.3562-3569, 2005.
Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study, J Clin Oncol, vol.23, issue.34, pp.8646-54, 2005. ,
Platinum-based chemotherapy plus cetuximab in head and neck cancer, N Engl J Med, vol.359, issue.11, pp.1116-1143, 2008. ,
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck, N Engl J Med, vol.375, pp.1856-1867, 2016. ,
Pembrolizumab for Platinum-and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study, J Clin Oncol, 2017. ,
, May, vol.10, issue.14, pp.1542-1549
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study, Ann Oncol, vol.22, issue.5, pp.1078-87, 2011. ,
, Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial, Lancet Oncol, vol.16, issue.5, pp.583-94, 2015.
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck ,
, J Clin Oncol, vol.27, issue.11, pp.1864-71, 2009.
Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer, 2017. ,
Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab, Clin Cancer Res, vol.22, issue.15, pp.3961-70, 2016. ,
Therapeutic insights from genomic studies of head and neck squamous cell carcinomas. Cancer Discov, vol.5, pp.239-283, 2015.,
DOI : 10.1158/2159-8290.cd-14-1205
URL : http://cancerdiscovery.aacrjournals.org/content/5/3/239.full.pdf
Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives, Cancer Metastasis Rev, vol.35, issue.3, pp.413-439, 2016. ,
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Ann Oncol, vol.28, issue.10, pp.2533-2538, 2017. ,
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer ,
, Ann Oncol, vol.26, issue.3, pp.556-61, 2015.
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER), Lancet Oncol, vol.15, issue.3, pp.267-74, 2014. ,
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial, Lancet Oncol, vol.16, issue.13, pp.1324-1358, 2015. ,
Clinical impact of extensive molecular profiling in advanced cancer patients, J Hematol Oncol, vol.10, issue.1, p.45, 2017. ,
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial, Cancer Discov, vol.7, issue.6, pp.586-595, 2017. ,
, Comprehensive genomic characterization of head and neck squamous cell carcinomas, Nature, vol.517, issue.7536, pp.576-82, 2015.
Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer, Clin Cancer Res, vol.22, issue.18, pp.4623-4656, 2016.,
DOI : 10.1158/1078-0432.ccr-16-0637
URL : http://clincancerres.aacrjournals.org/content/22/18/4623.full.pdf
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors, J Clin Oncol, vol.35, issue.3, pp.352-360, 2017. ,
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma, Ann Oncol, vol.26, issue.7, pp.1476-80, 2015. ,
TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin-and cetuximabrefractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO), Ann Oncol, 2015. ,